GLI1 and pancreatic neoplasm: Gli1 activation in these cells was inhibited by Smo knockdown with short interfering RNA [112], indicating the potential of targeting Smo as a therapeutic approach to interfere with the pro-tumorigenic SHH signaling in the microenvironment of pancreatic cancer.